<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822081</url>
  </required_header>
  <id_info>
    <org_study_id>COM0501</org_study_id>
    <nct_id>NCT00822081</nct_id>
  </id_info>
  <brief_title>Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bp Consulting, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bp Consulting, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy and tolerability/comfort of brimonidine/timolol and
      dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. In an
      investigator masked randomization process, each subject is allocated to recieve either
      brimonidine/timolol or dorzolamide/timolol as fixed-combination monotherapy or as an
      adjuctive to a prostoglandin analogue for a period of 12 weeks. After screening, patient
      returns at baseline, Month 1, and Month 3 for ophthalmic evaluations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean IOP.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient tolerability/comfort measured by Likert scale.</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>brimonidine/timolol. Fixed-combination monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dorzolamide/timolol. Fixed-combination monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prostaglandin analogue+ brimonidine/timolol fixed combination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prostaglandin analogue+dorzolamide/timolol fixed combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination</intervention_name>
    <description>1 drop BID in each eye</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Combigan.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination</intervention_name>
    <description>1 drop BID in each eye</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cosopt.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.</intervention_name>
    <description>1 drop BID in each eye</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Combigan.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.</intervention_name>
    <description>1 drop BID in each eye</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Cosopt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 18 yrs.

          -  Female subjects of childbearing potential must have negative pregnancy test and
             provide contraception.

          -  Subjects must have confirmed diagnosis of primary open-angle glaucoma or ocular
             hypertension in both eyes.

          -  Subjects who are or have been insufficiently responsive to IOP reducing monotherapy
             and use of either study medication is deemed appropriate.

          -  Subjects able to complete questionnaires and provide informed consent.

        Exclusion Criteria:

          -  Female subjects who are pregnant, planning to become pregnant during study period,
             breast feeding or not practicing a reliable method of birth control.

          -  Subjects wherein the study drugs are containdicated.

          -  Subjects who have had introcular surgery with 6 months (3 months for laser).

          -  Subjects with known side effects/ allergy or sensitivity to any component of study
             treatments.

          -  Subjects with any uncontrolled systemic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>January 13, 2009</last_update_submitted>
  <last_update_submitted_qc>January 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Hand</name_title>
    <organization>Allergan, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

